Osteologix, Inc. (OLGX.OB) Announces Patent Allowance for Novel Osteoporosis Drug
Osteologix, Inc. announced this morning that is has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its U.S. Patent Application titled "Water-Soluble Strontium Salts for Use in Treatment of Cartilage and/or Bone Conditions." The reported allowance of claims covers the treatment of osteoporosis and related bone conditions using NB S101 (strontium malonate), the company's lead osteoporosis drug candidate. The company anticipates that the patent will be issued in the second half of 2009. According to the press release, the patent's 20-year term would expire in 2024. Additionally, the company has a number of other…